Synthesis, in vitro safety and antioxidant activity of new pyrrole hydrazones
By:
References
- 1. G. Lavanya, V. Padmavathi and A. Padmaja, Synthesis and antioxidant activity of 1,4-[bis(3-arylmethanesulfonyl pyrrolyl and pyrazolyl)]benzenes,
J. Braz. Chem. Soc .25 (2014) 1200–1207;https://doi.org/10.5935/0103-5053.20140097">https://doi.org/10.5935/0103-5053.20140097 - 2. S. Durgamma, A. Muralikrishna, V. Padmavathi and A. Padmaja, Synthesis and antioxidant activity of amido-linked benzoxazolyl/benzothiazolyl/benzimidazolyl-pyrroles and pyrazoles,
Med. Chem. Res. 23 (2014) 2916–2929;https://doi.org/10.1007/s00044-013-0884-x">https://doi.org/10.1007/s00044-013-0884-x - 3. S. K. Sridhar, M. Saravanan and A. Ramesh, Synthesis and antibacterial screening of hydrazones, Schiff and Mannich bases of isatin derivatives,
Eur. J. Med. Chem. 36 (2001) 615–625;https://doi.org/10.1016/S0223-5234(01)01255-7">https://doi.org/10.1016/S0223-5234(01)01255-7 - 4. S. I. Alqasoumi, M. M. Ghorab, Z. H. Ismail, S. M. Abdel-Gawad, M. S. El-Gaby and H. M. Aly, Novel antitumor acetamide, pyrrole, pyrrolopyrimidine, thiocyanate, hydrazone, pyrazole, isothiocyanate and thiophene derivatives containing a biologically active pyrazole moiety,
Arzneimittelforschung 59 (2009) 666–671;https://doi.org/10.1055/s-0031-1296457">https://doi.org/10.1055/s-0031-1296457 - 5. Y. Xia, C. Fan, B. X. Zhao, J. Zhao, D. S. Shin and J. Y. Miao, Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1
H -pyrazole-5-carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells,Eur. J. Med. Chem. 43 (2008) 2347–2353;https://doi.org/10.1016/j.ejmech.2008.01.021">https://doi.org/10.1016/j.ejmech.2008.01.021 - 6. R. M. Mohareb, H. D. Fleita and O. K. Sakka, Novel synthesis of hydrazide-hydrazone derivatives and their utilization in the synthesis of coumarin, pyridine, thiazole and thiophene derivatives with antitumor activity,
Molecules 16 (2010) 16–27;https://doi.org/10.3390/molecules16010016">https://doi.org/10.3390/molecules16010016 - 7. A. A. El-Tombary and S. A. M. El-Hawash, Synthesis, antioxidant, anticancer and antiviral activities of novel quinoxalinehydrazone derivatives and their acyclic C-nucleosides,
Med. Chem .10 (2014) 521–532;https://doi.org/10.2174/15734064113096660069">https://doi.org/10.2174/15734064113096660069 - 8. M. O. Puskullu, H. Shirinzadeh, M. Nenni, H. Gurer-Orhan and S. Suzen, Synthesis and evaluation of antioxidant activity of new quinoline-2-carbaldehyde hydrazone derivatives: bioisosteric melatonin analogues,
J. Enzyme Inhib. Med. Chem. 31 (2016) 121–125;https://doi.org/10.3109/14756366.2015.1005012">https://doi.org/10.3109/14756366.2015.1005012 - 9. H. S. Kareem, A. Ariffin, N. Nordin, T. Heidelberg, A. Abdul-Aziz, K. W. Kong and W. Yehye, Correlation of antioxidant activities with theoretical studies for new hydrazone compounds bearing a 3,4,5-trimethoxy benzyl moiety,
Eur. J. Med. Chem. 103 (2015) 497–505;https://doi.org/10.1016/j.ejmech.2015.09.016">https://doi.org/10.1016/j.ejmech.2015.09.016 - 10. M. Georgieva, D. Tzankova, S. Vladimirova and A. Bijev, Evaluation of a group of pyrrole derivatives as tuberculostatic agents,
CBU Int. Conf. Innov. Sci. Ed. 5 (2017) 1083–1091;https://doi.org/10.12955/cbup.v5.1075">https://doi.org/10.12955/cbup.v5.1075 - 11. A. Bijev and M. Georgieva, Pyrrole-based hydrazones synthesized and evaluated in vitro as potential tuberculostatics,
Lett. Drug Des. Discov. 7 (2010) 430–437;https://doi.org/10.2174/157018009789108268">https://doi.org/10.2174/157018009789108268 - 12. A. Kajal, S. Bala, N. Sharma, S. Kamboj and V. Saini, Therapeutic potential of hydrazones as anti-inflammatory agents,
Int. J. Med. Chem. 11 (2014) 1–11;https://doi.org/10.1155/2014/761030">https://doi.org/10.1155/2014/761030 - 13. K. N. de Oliveira, P. Costa, J. R. Santin, L. Mazzambani, C. Bürger, C. Mora, R. J. Nunes and M. M. de Souza, Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonylhydrazones,
Bioorg. Med. Chem. 19 (2011) 4295–4306;https://doi.org/10.1016/j.bmc.2011.05.056">https://doi.org/10.1016/j.bmc.2011.05.056 - 14. C. M. Leal, S. L. Pereira, A. E. Kummerle, D. M. Leal, R. Tesch, C. M. de Sant’Anna, C. A. Fraga, E. J. Barreiro, R. T. Sudo and G. Zapata-Sudo, Antihypertensive profile of 2-thienyl-3,4-methylene dioxy benzoylhydrazone is mediated by activation of the A2A adenosine receptor,
Eur. J. Med. Chem. 55 (2012) 49–57;https://doi.org/10.1016/j.ejmech.2012.06.056">https://doi.org/10.1016/j.ejmech.2012.06.056 - 15. L. Yurttaş, Y. Özkay, Z. A. Kaplancıklı, Y. Tunalı and H. Karaca, Synthesis and antimicrobial activity of some new hydrazone-bridged thiazole-pyrrole derivatives,
J. Enzyme Inhib. Med. Chem. 28 (2013) 830–835;https://doi.org/10.3109/14756366.2012.688043">https://doi.org/10.3109/14756366.2012.688043 - 16. O. O. Ajani, C. A. Obafemi, O. C. Nwinyi and D. A. Akinpelu, Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives,
Bioorg. Med. Chem. 18 (2010) 214–221;https://doi.org/10.1016/j.bmc.2009.10.064">https://doi.org/10.1016/j.bmc.2009.10.064 - 17. R. J. Vaigunda, D. Sriram, S. K. Patel, I. V. Reddy, N. Bharathwajan, J. Stables and P. Yogeeswari, Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydra-zone pharmacophore,
Eur. J. Med. Chem. 42 (2007) 146–151;https://doi.org/10.1016/j.ejmech.2006.08.010">https://doi.org/10.1016/j.ejmech.2006.08.010 - 18. J. R. Dimmock, S. C. Vashishtha and J. P. Stables, Anticonvulsant properties of various acetylhydra-zones, oxamoylhydrazones and semicarbazones derived from aromatic and unsaturated carbonyl compounds,
Eur. J. Med. Chem. 35 (2000) 241–248;https://doi.org/10.1016/S0223-5234(00)00123-9">https://doi.org/10.1016/S0223-5234(00)00123-9 - 19. B. G. Giménez, M. S. Santos, M. Ferrarini and J. P. S. Fernandes, Evaluation of blockbuster drugs under the Rule-of-five,
Pharmazie 65 (2010) 148–152;https://doi.org/10.1691/ph.2010.9733">https://doi.org/10.1691/ph.2010.9733 - 20. C. A. Lipinski, Lead- and drug-like compounds: the rule-of-five revolution,
Drug Discov. Today Technol. 1 (2004) 337–341;https://doi.org/10.1016/j.ddtec.2004.11.007">https://doi.org/10.1016/j.ddtec.2004.11.007 - 21. T. P. Kenakin,
Pharmacology in Drug Discovery and Development , 2nd ed., Elsevier, Amsterdam 2017, pp. 157–191. - 22. J. F. Varghese, R. Patel and U. C. S. Yadav, Novel insights in the metabolic syndrome-induced oxidative stress and inflammation-mediated atherosclerosis,
Curr. Cardiol. Rev. 14 (2018) 4–14;https://doi.org/10.2174/1573403X13666171009112250">https://doi.org/10.2174/1573403X13666171009112250 - 23. H. Yaribeygi, Y. Panahi, B. Javadi and A. Sahebkar, The underlying role of oxidative stress in neurodegeneration: A mechanistic review,
CNS Neurol. Dis.-Drug Targets 17 (2018) 207–215;https://doi.org/10.2174/1871527317666180425122557">https://doi.org/10.2174/1871527317666180425122557 - 24. L. A. Pham-Huy, H. He and C. Pham-Huy, Free radicals, antioxidants in disease and health,
Int. J. Biomed. Sci. 4 (2008) 89–96. - 25. M. Chand, Rajeshwari, A. Hiremathad, M. Singh, M. A. Santos and R. S. Keri, A review on antioxidant potential of bioactive heterocycle benzofuran: Natural and synthetic derivatives,
Pharmacol. Rep. 69 (2017) 281–295;https://doi.org/10.1016/j.pharep.2016.11.007">https://doi.org/10.1016/j.pharep.2016.11.007 - 26. M. Miceli, E. Roma, P. Rosa, M. Feroci, M. A. Loreto, D. Tofani and T. Gasperi, Synthesis of benzofuran-2-one derivatives and evaluation of their antioxidant capacity by comparing DPPH assay and cyclic voltammetry,
Molecules 23 (2018) 710–726;https://doi.org/10.3390/molecules23040710">https://doi.org/10.3390/molecules23040710 - 27. A. A. Shanty, J. E. Philip, E. J. Sneha, M. R. P. Kurup, S. Balachandran and P. V. Mohanan, Synthesis, characterization and biological studies of Schiff bases derived from heterocyclic moiety,
Bioorg. Chem. 70 (2017) 67–73;https://doi.org/10.1016/j.bioorg.2016.11.009">https://doi.org/10.1016/j.bioorg.2016.11.009 - 28. A. A. Shanty and P. V. Mohanan, Heterocyclic Schiff bases as non toxic antioxidants: Solvent effect, structure activity relationship and mechanism of action,
Spectrochim. Acta A 192 (2018) 181–187;https://doi.org/10.1016/j.saa.2017.11.019">https://doi.org/10.1016/j.saa.2017.11.019 - 29. K. M. Khan, Z. Shah, V. U. Ahmad, M. Khan, M. Taha, F. Rahim, S. Ali, N. Ambreen, S. Perveen, M. I. Choudhary and W. Voelter, 2,4,6-Trichlorophenylhydrazine Schiff bases as DPPH radical and super oxide anion scavengers,
Med. Chem. 8 (2012) 452–461;https://doi.org/10.2174/1573406411208030452">https://doi.org/10.2174/1573406411208030452 - 30. N. Belkheiri, B. Bouguerne, F. Bedos-Belval, H. Duran, C. Bernis, R. Salvayre, A. Nègre-Salvayre and M. Baltas, Synthesis and antioxidant activity evaluation of a syringic hydrazones family,
Eur. J. Med. Chem. 45 (2010) 3019–3026;https://doi.org/10.1016/j.ejmech.2010.03.031">https://doi.org/10.1016/j.ejmech.2010.03.031 - 31. A. Guillouzo, Liver cell models in in vitro toxicology,
Environ. Health Perspect. 106 (Suppl. 2) (1998) 511–532;https://doi.org/10.1289/ehp.98106511">https://doi.org/10.1289/ehp.98106511 - 32. P. Ertl, B. Rohde and P. Selzer, Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties,
J. Med. Chem. 43 (2000) 3714–3717;https://doi.org/10.1021/jm000942e">https://doi.org/10.1021/jm000942e - 33. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates,
J. Med. Chem. 45 (2002) 2615–2623;https://doi.org/10.1021/jm020017n">https://doi.org/10.1021/jm020017n - 34. А. Bijev, Synthesis and preliminary screening of carbohydrazides and hydrazones of pyrrole derivatives as potential tuberculostatics,
Arzneimittelforschung 56 (2006) 96–103;https://doi.org/10.1055/s-0031-1296708">https://doi.org/10.1055/s-0031-1296708 - 35. B. C. Evans, C. E. Nelson, S. S. Yu, K. R. Beavers, A. J. Kim, H. Li, H. M. Nelson, T. D. Giorgio and C. L. Duvall, Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs,
J. Vis. Exp. 73 (2013) e50166;https://doi.org/10.3791/50166">https://doi.org/10.3791/50166 - 36. W. Brand-Williams, M. E. Cuvelier and C. Berset, Use of a free radical method to evaluate antioxidant activity,
LWT-Food Sci. Technol. 28 (1995) 25–30;https://doi.org/10.1016/S0023-6438(95)80008-5">https://doi.org/10.1016/S0023-6438(95)80008-5 - 37. R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang and C. Rice-Evans, Antioxidant activity applying an improved ABTS radical cation decolorization assay,
Free Radic. Biol. Med. 26 (1999) 1231–1237;https://doi.org/10.1016/S0891-5849(98)00315-3">https://doi.org/10.1016/S0891-5849(98)00315-3 - 38. O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, Protein measurement with the Folin phenol reagent,
J. Biol. Chem .193 (1951) 265–275. - 39. D. Mansuy, A. Sassi, P. M. Dansette and M. Plat, A new potent inhibitor of lipid peroxidation
in vitro andin vivo , the hepatoprotective drug anisyldithiolthione,Biochem. Biophys. Res. Commun .135 (1986) 1015–1021;https://doi.org/10.1016/0006-291X(86)91029-6">https://doi.org/10.1016/0006-291X(86)91029-6 - 40. C. Deby and R. Goutier, New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases,
Biochem. Pharmacol .39 (1990) 399–405;https://doi.org/10.1016/0006-2952(90)90043-K">https://doi.org/10.1016/0006-2952(90)90043-K - 41. H. Gao and X. Gao,
Recent Progress in Blood-brain Barrier Transportation Research, inBrain Targeted Drug Delivery System –A Focus on Nanotechnology and Nanoparticulates , 1sted. Elsevier, Amsterdam 2019, pp. 469–481. - 42. Y. H. Zhao, M. H. Abraham, J. Lee, A. Hersey, C. N. Luscombe, G. Beck, B. Sherborne and I. Cooper, Rate-limited steps of human oral absorption and QSAR studies,
Pharm. Res. 19 (2002) 1446–1457. - 43. D. Schuster, C. Laggner and T. Langer, Why drugs fail – a study on side effects in new chemical entities,
Curr. Pharm. Des .11 (2005) 3545–3559;https://doi.org/10.2174/138161205774414510">https://doi.org/10.2174/138161205774414510 - 44. W. C. Maddrey, Drug-induced hepatotoxicity,
J. Clin. Gastroenterol .39 (2005) S83–S89;https://doi.org/10.1097/01.mcg.0000155548.91524.6e">https://doi.org/10.1097/01.mcg.0000155548.91524.6e - 45. J. Hou, W. Zhao, Z. N. Huang, S. M. Yang, L. J. Wang, Y. Jiang, Z. S. Zhou, M. Y. Zheng, J. L. Jiang, S. H. Li and F. N. Li, Evaluation of novel
N -(piperidine-4-yl)benzamide derivatives as potential cell cycle inhibitors in HepG2 cells,Chem. Biol. Drug Des. 86 (2015) 223–231;https://doi.org/10.1111/cbdd.12484">https://doi.org/10.1111/cbdd.12484 - 46. P. Martins, J. Jesus, S. Santos, L. R. Raposo, C. Roma-Rodrigues, P. V. Baptista and A. R. Fernandes, Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine’s tool box,
Molecules 20 (2015) 16852–16891;https://doi.org/10.3390/molecules200916852">https://doi.org/10.3390/molecules200916852 - 47. S. Knasmüller, W. Parzefall, R. Sanyal, S. Ecker, C. Schwab, M. Uhl, V. Mersch-Sundermann, G. Williamson, G. Hietsch, T. Langer, F. Darroudi and A. T. Natarajan, Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens,
Mutat. Res./Fund. Mol. Mech. Mutagen. 402 (1998) 185–202;https://doi.org/10.1016/S0027-5107(97)00297-2">https://doi.org/10.1016/S0027-5107(97)00297-2 - 48. V. Mersch-Sundermann, S. Knasmüller, X. J. Wu, F. Darroudi and F. Kassie, Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents,
Toxicology 198 (2004) 329–340;https://doi.org/10.1016/j.tox.2004.02.009">https://doi.org/10.1016/j.tox.2004.02.009 - 49. Y. Sıcak, E. E. Oruç-Emre, M. Öztürk, T. Taşkın-Tok and A. Karaküçük-Iyidoğan, Novel fluorine-containing chiral hydrazide-hydrazones: Design, synthesis, structural elucidation, antioxidant and anticholinesterase activity, and
in silico studies,Chirality (2019)https://doi.org/10.1002/chir.23102">https://doi.org/10.1002/chir.23102 ; ahead of print. - 50. D. X. Tan, L. D. Chen, B. Poeggeler, L. C. Manchester and R. J. Reiter, Melatonin: a potent, endogenous hydroxyl radical scavenger,
Endocr. J. 1 (1993) 57–60. - 51. R. Reiter, L. Tang, J. J. Garcia and A. Munoz-Hoyos, Pharmacological actions of melatonin in oxygen radical pathophysiology,
Life Sci. 60 (1997) 2255–2271;https://doi.org/10.1016/S0024-3205(97)00030-1">https://doi.org/10.1016/S0024-3205(97)00030-1 - 52. R. Hardeland, Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance,
Endocrine 27 (2005) 119–130;https://doi.org/10.1385/ENDO:27:2:119">https://doi.org/10.1385/ENDO:27:2:119 - 53. L. Deferme, J. J. Briedé, S. M. H. Claessen, D. G. J. Jennen, R. Cavill and J. C. S. Kleinjans, Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach,
Toxicology 306 (2013) 24–34;https://doi.org/10.1016/j.tox.2013.02.001">https://doi.org/10.1016/j.tox.2013.02.001
Language: English
Page range: 303 - 324
Accepted on: Sep 12, 2019
Published on: Feb 17, 2020
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2020 Diana Tzankova, Stanislava Vladimirova, Denitsa Aluani, Yordan Yordanov, Lily Peikova, Maya Georgieva, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.